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Therapy-related myeloid neoplasms (t-MN) are well-recognized complications of high-dose cytotoxic therapy
(HDT), such as autologous stem cell transplantation (ASCT). Clonal marrow cytogenetic abnormalities (CMCA)
in the setting of normal bone marrow pathology have also been reported after HDT, but their signiﬁcance
remains unclear. We retrospectively evaluated occurrences of CMCA and t-MN in 785 patients treated with
HDT at Johns Hopkins University between 1997 and 2007. Most patients received ASCT, but 106 patients who
received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institu-
tional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. Twenty-two
patients developed t-MN, with an estimated cumulative incidence of 3.5% at 4 years. Eleven patients
developed isolated CMCA, either transient or persistent without pathologic evidence of t-MN. Altogether,
only 20 of the patients with reported CMCA subsequently developed t-MN during the follow-up period.
Therefore, in the absence of pathologic evidence of t-MN, CMCA should not be considered diagnostic of t-MN.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Reported incidence rates of therapy-related myeloid
neoplasms (t-MN) after autologous blood or marrow trans-
plantation (ASCT), vary from 1% to 20% [1-9]. The reported
incidence rates of t-MN after ASCT generally appear higher
than those reported after multiple cycles of conventional-
dose therapy [10]. Though t-MN are usually associated with
clonal marrow cytogenetic abnormalities (CMCA) [11,12], it is
not clear that isolated therapy-related CMCA, those that
occur in the setting of normal bone marrow pathology, are
always associated with t-MN. In fact, there are several re-
ports of patients developing CMCAwithout other evidence of
t-MN after ASCT [2,9,13-19], but the signiﬁcance of this
ﬁnding is uncertain. Several of our patients developed either
transient or persistent isolated CMCA after high-dose ther-
apy (HDT) without progression to t-MN over prolonged
follow-up. As the prognosis of t-MN is extremely poor, with a
median survival of less than 1 year unless cured with allo-
geneic stem cell transplantation [13,20-22], a better under-
standing of the signiﬁcance of isolated CMCA after HDT is
critical. Our aim was to evaluate occurrences of isolated
CMCA and t-MN in patients who received HDT at Johns
Hopkins Hospital between 1997 and 2006 via a retrospective
review ofmedical records. One hundred and six patients who
received high-dose cyclophosphamide (HiCy) without ASCT
were also included in this study. This therapy is ouredgments on page 1137.
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ders and severe aplastic anemia (SAA) [23,24].
MATERIALS AND METHODS
Subjects
We retrospectively identiﬁed all patients who underwent HDT at our
institution between 1997 and 2006 (Table 1). Eligible patients were 18 years
of age or older at time of treatment and had an initial diagnosis of indolent
non-Hodgkin’s lymphoma (iNHL), chronic myeloid leukemia (CML), acute
myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple
myeloma (MM), Hodgkin’s lymphoma, diffuse large B cell lymphoma
(DLBCL), acute lymphoblastic leukemia (ALL), or SAA. Clinical data were
collected from the medical records of 785 consecutive patients. The infor-
mation included age, diagnosis, status at time of HDT, date of treatment,
date of last follow-up, disease status at follow-up, and results of bone
marrow biopsy, cytogenetic analysis, and FISH studies. A subset of patients
also had interphase FISH analysis for as part of their follow-up, as these tests
came on-line clinically. Therefore, for patients with t-MN (Table 2) FISH
results were included only if a patient had no cytogenetic analyses available.
However, for patients with isolated CMCAs, all available FISH results were
reported to depict the most complete portrayal available of the evolution of
chromosome abnormalities. Acute leukemia that occurred after an original
diagnosis of AML was only considered t-MN if there was not only a different
karyotype, but also a distinctly different clinical presentation regarding
dysplasia and white blood cell count. Among the records of patients with t-
MN, abnormal cytogenetic analyses were further reviewed for details of
previous cytotoxic therapy and other relevant clinical information. Our
center’s recommended follow-up includes periodic bone marrow exami-
nations with routine morphology, ﬂow cytometry, and cytogenetic analysis;
however, the ﬁnal decision regarding follow-up is left to the discretion of the
attending physician and patient. Every available bone marrow biopsy result
was included for the patients listed in Tables 2 and 3. All patients with CML
received HDT between 1997 and 1999, before the standard use of imatinib.
Patients were treated according to institutional review boardeapproved
disease-speciﬁc ASCTor HiCy regimens. Preparative regimens for ASCT were
Cy 200 mg/kg over 4 days with either 1200 cGy total body irradiation
(CyTBI) or busulfan 16 mg/kg orally over 4 days, with dosing individualized
based on ﬁrst dose pharmacokinetics (BuCy) [25]. Cy 200 mg/kg alone
(HiCy) was used for all 48 patients with SAA [23] as well as 58 patients with
low-grade lymphoma or myeloma [24]. Approval for the analysis wasTransplantation.
Table 1
Patient Characteristics
Patient
Characteristics
Total
Patients
Patients with
t-MN
Patients with
Isolated CMCA
No. patients 785 22 11
Age, median, yr 51 58 56
Male 468 16 6
Female 317 6 5
Diagnosis
AA 48 1 3
ALL 11 0 1
AML 36 1 0
CLL 28 2 1
CML 15 0 0
DLBCL 181 7 3
HL 100 0 1
MM 129 1 0
iNHL 237 10 2
Follow-up, median, yr 2.2 4.8 7.3
AA indicates aplastic anemia; HL, Hodgkin lymphoma; iNHL, indolent non-
Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; CLL, chronic
lymphocytic lymphoma; ALL, acute lymphoblastic lymphoma; MM, multi-
ple myeloma; CML, chronic myeloid leukemia; AML, acute myeloid leuke-
mia; t-MN, therapy-related myeloid neoplasms; CMCA, clonal marrow
cytogenetic abnormalities.
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reported up to August 2012.
Pathology
Standard French, American, and British and World Health Organization
criteria were used for the diagnosis of t-MN criteria, myelodysplastic syn-
drome (MDS), AML, and ALL [26,27]. The time of diagnosis of t-MN after HDT
was the ﬁrst date when results of bone marrow pathology revealed a
diagnosis of t-MN.
Cytogenetics
Cytogenetic analyses were performed as per routine post-
transplantation follow-up. Abnormalities were described using Interna-
tional System for Human Cytogenetic Nomenclature (2009) criteria [28].
Cytogenetic abnormalities were considered clonal only if 2 or more cells had
the abnormality. Cytogenetic abnormalities that are normal variants were
not considered CMCA, including pericentric inversion of chromosome 9 and
loss of the Y chromosome, which is commonly observed in older males
without hematologic disease [29]. Of the entire cohort, this included 2 pa-
tients with a transient isolated loss of chromosome Y, 1 patient with a
pericentric inversion of chromosome 9, and another with both inversion 9
and loss of Y. Cytogenetic abnormalities were considered isolated in the
absence of bone marrow morphology consistent with pathologic diagnosis
of MDS/AML. These isolated abnormalities were classiﬁed as transient if
there were a subsequent analysis revealing a normal karyotype, whereas
they were classiﬁed as persistent if there were no subsequent analyses
demonstrating a normal karyotype. All cytogenetic analyses were done on-
site, except the 5 results that are annotated “per note” in Tables 2 and 3.
Statistics
The aim of this study was to report discovered occurrences of isolated
CMCA and estimate the cumulative incidence of t-MN among 785 patients
after HDT. Patient characteristics were summarized by mean, median,
standard deviation, range, and frequency. We estimated the cumulative
incidence of discovered cases of isolated CMCAs to report a possible lower
bound of the true incidence rate of these events. Cumulative incidence of
t-MN and discovered cases of isolated CMCA were estimated via Kaplan-
Meier approach. The time-to-event interval was deﬁned from date of
initial HDT. Patients who relapsed, progressed, or died before t-MN or iso-
lated CMCA were treated as noninformative censoring to t-MN and CMCA
events. In addition, patients who developed t-MN were no longer at risk of
developing isolated CMCA. Therefore, patients who experienced t-MN
before isolated CMCA was detected were censored at the time t-MN
developed when estimating cumulative incidence of discovered cases of
isolated CMCA. Patients with detected CMCAwere still at risk of developing
t-MN. Thus, for t-MN incidence estimation, an event was deﬁned from time
of HDT to diagnosis of t-MN. Patients who did not experience isolated CMCA
or t-MN were censored at the time of last follow-up in the case of no prior
occurrence of relapse, progression, or death. All analyses were performed inR 2.15.1 statistical software (The R Project for Statistical Computing, Vienna,
Austria).
RESULTS
The patient characteristics are displayed in Table 1. A total
of 785 patients received HDT between 1997 and 2006,
including 106 who received HiCy. Their diagnoses were as
follows: 237 with 129 iNHL, 181 with DLBCL, 129 with MM,
100 with Hodgkin lymphoma, 48 with SAA, 36 with AML, 28
with CLL, 15 with CML, and 11 with ALL. The median age was
51 years and the median follow-up was 2.2 (range, 0 to 14.2)
years for all patients and 3.5 (range, 0 to 14.2) years for those
who have not died or relapsed.
t-MN
t-MN developed in 22 patients. The estimated 4-year
cumulative incidence of t-MN was 3.5% (95% conﬁdence in-
terval [CI], 1.6% to 5.4%). The median follow-up for patients
who developed t-MN was 4.8 (range, .8 to 15.2) years, and
the median time to the diagnosis was 3.1 years (range, .8 to
12.9) from HDT (Table 2). These patients were older than the
study population with a median age of 58. Of note, 73% were
males, compared with 60% in the study population. The
speciﬁc pathologic diagnosis was MDS in all but 4 patients, 4
of whom had a diagnosis of AML, 2 with dysplastic feature
(Table 2, patient nos. 6 and 17), and 2 without (Table 2, pa-
tient nos. 14 and 18). One patient developed ALL after HDT
(Table 2, patient no. 20). This patient initially developed
complex karyotype 3 years after ASCT for NHL, but concur-
rent bone marrow pathology was unremarkable. Subse-
quently, the patient was lost to follow-up until 6.3 years from
ASCT, when he presented with similar cytogenetic abnor-
malities and bone marrow pathology of unequivocal ALL
absent any myeloid antigens. Six weeks later, during treat-
ment for ALL, bone marrow pathology was consistent with
MDS.
Of the patients who developed t-MN, 1 each had an initial
diagnosis SAA, AML, or MM, 2 had CLL, 7 had DLBCL, and 10
had iNHL. Although iNHL only accounts for 31% of the study
population, it accounts for 45% of patients with t-MN. The
group with the largest proportion of patients with t-MN was
CLL, with 9%. The only patient with t-MN with an original
diagnosis of AML (Table 2, patient no. 2) originally presented
with 47,XYþ21 [3]/46,XY [17] and normal peripheral blood
counts and no dysplasia. Before HDT, the patient was in
complete remission with a normal karyotype. After HDT the
patient developed cytopenias, marrow dysplasia and the
cytogenetic abnormality 46,XY,þ1,der(1;7)(q10;p10) [8]/
46,XY [12], which was conﬁrmed on subsequent evaluations.
Therefore, this case was classiﬁed as t-MN as opposed to
relapsed disease. Of the 34 patients with the initial diagnosis
of AML, 17 relapsed after HDT, all but 3 within 1 year. In
addition, 8 died of complications of HDT. Outcomes were
similar with ALL, with 7 of the 11 patients dead or relapsed
within 1 year. None of the 4 remaining patients developed t-
MN.
Of the 22 patients who developed t-MN, only 6 patients
were in ﬁrst complete remission at time of HDT, 2 were in
second complete remission, and the remainder had active
disease. In addition, the majority were relatively heavily
pretreated before HDT. The median number of cycles of
chemotherapy administered was 6, and 13 patients were
treated with more than 1 chemotherapy regimen. Only 1
patient, who had SAA, received no prior cytotoxic therapy. All
but 3 patients received alkylating agents, 16 in combination
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total of 13 patients were treated with vinca alkaloids, all in
combination with other agents. Five patients received ﬂu-
darabine, 1 as monotherapy. Conditioning regimens in these
patients consisted of CyTBI for 11 patients, BuCy in nine, and
HiCy in 2 patients. Of 106 patients who received HiCy, 2
developed t-MN with initial diagnoses of AA and iNHL.
Chromosomal analysis was available in 21 of the
patients who developed t-MN (Table 2). Of those, all but 1
patient had abnormal cytogenetics, all of which contained
CMCA classiﬁed as unfavorable risk in the setting of t-MN
[11,30]. Eighteen patients had complex abnormalities,
whereas 3 had a single cytogenetic abnormality. Abnor-
malities involving chromosome 7 were the most common.
The abnormal clone involved a median of 83% of the cells
analyzed. The median interval from HDT to initial CMCA
detection was 3.1 (range, .8 to 12.9) years. Three of these
patients (Table 2, patient nos. 12, 20 and 21) initially
developed CMCA with normal bone marrow pathology, no
change in blood counts, and no clinical signs or symptoms
of t-MN, preceding the deﬁnitive morphologic diagnosis of
t-MN by 1.2 to 3.2 years.
Isolated CMCA
Of the patients who had karyotype evaluation after HDT,
isolated CMCA were found in 11 patients, who as of the last
follow-up date have not shown bone marrow pathology
consistent with MDS or AML (Table 3). The median age of 56
was older than that of the general population. With 6 males
and 5 females, the gender distribution resembled that of the
study population. The median time to the detection of the
CMCA after HDT was 2.0 (range, .3 to 9.6) years. All but 1 of
these patients (Table 3, patient no. 8) had at least 2 years of
disease-free follow-up after detection of the cytogenetic
abnormality, including normal bone marrow evaluations.
The median follow-up from the date of ﬁrst discovery of the
CMCA was 4.2 (range, 1.0 to 9.3) years, with median follow-
up from HDT of 7.3 years (range, 3 to 11.6) years. All of
these patients were in complete remissionwith no histologic
evidence of t-MN as of last follow-up at JHU. Patient no. 8
was in complete remission at last follow-up, but died
9 months later of unknown cause, per public records. Patient
nos. 1 through 4 had isolated CMCA that were transient with
normal karyotype on 1 or more subsequent analyses. Four
patients had dysplasia in their marrow at some point that did
not meet World Health Organization criteria for MDS
morphology. All 3 patients with AA had cytopenias after HDT,
but only 1 (Table 3, patient no. 1) had blood counts that were
below the pretreatment values, which occurred transiently
immediately after HDT. Of the remaining 8 patients, all of
whom had normal blood counts before HDT, 4 had cytope-
nias brieﬂy after HDT. Because of the nature and limitations
of the data, it was not possible to estimate the rate at which
these abnormalities occurred, but rather only at which they
were discovered, with the premise that the incidence of
occurrence is not likely to be lower this. The estimated cu-
mulative incidence of discovering cases of isolated CMCA
was 2.3% (95% CI, .8 to 3.8%) at 4 years.
Of the 11 patients in whom isolated CMCA were found,
only 3 received more than 1 prior chemotherapy regimen
and 3 patients with the initial diagnoses of SAA received no
chemotherapy before HDT. Of the 8 previously treated pa-
tients, 5 were in remission at time of HDT. All those treated
received alkylating agents. Seven patients received anthra-
cyclines and vinca alkaloids, 2 of whom also receivedetoposide. One patient received ﬂudarabine as part of com-
bination therapy. Preparative regimens of CyTBI or HiCywere
used in 4 patients each and BuCy in 3.
The CMCA in this group include anomalies that are often
associated with t-MN, involving chromosomes 1, 5q, 7, 9q,
and 20q [11,30]. Cytogenetic abnormalities involving chro-
mosome 7 were the most common, reported in 6 patients.
Deletions or loss of chromosome 20 were reported in 4 pa-
tients. The abnormal clone involved a median of 39% of the
cells analyzed. Of note, the t(8;21)(q22;p11.2) in patient no. 6
is not the classic t(8;21)(q22;q22) translocation seen in core-
binding factor AML.
Of note, the patients with SAA represent over one quarter
of the reported isolated CMCA cases but only about 5% of the
total population. The 48 patients with SAA, which represent
almost one half of the total HiCy cohort, had received no
prior cytotoxic therapy. In contrast, almost all of the ASCT
group had been treated before HDT. In addition, as part of
their follow-up, the patients with SAA, and therefore the
HiCY cohort in general, likely had more bone marrow and
karyotype evaluations than the general population, enabling
the discovery of more abnormalities than the general pop-
ulation. These factors and the small number of positive cases
make it difﬁcult to compare the 2 HDT groups. Therefore, the
HiCy cohort was not evaluated separately.
DISCUSSION
This study reports the follow-up of 785 patients who
received HDT at our institution. The estimated cumulative
incidence of t-MN was 3.5% (95% CI, 1.6% to 5.4%) at 4 years.
This incidence lies in the range of those previously reported;
however, the true incidence is possibly higher. Although the
median follow-up of all eligible patients who did not die or
relapse was 3.5 years, t-MN can develop at least up to
10 years after cytotoxic therapy [1,3,31].
The most notable aspect of this analysis is the ﬁnding that
in 11 patients, isolated CMCA were discovered, 4 of which
were detected transiently. The isolated CMCA include
anomalies that are often associated with t-MN.
There are several limitations to the interpretation of our
data. Though follow-up after detection of the CMCA was at
least 2 years in all but 2 patients, withmedian of over 4 years,
it is possible that t-MN could still develop in these patients.
Furthermore, although part of our recommended follow-up
after HDT, routine bone marrow karyotype evaluation was
not performed in all patients, and some returned to their
home institution and were lost to follow-up, and conse-
quently cases of isolated CMCA would have been missed.
Therefore, within our reported time period, the number of
cases of isolated CMCA after HDT þ/ ASCT is very likely
higher than reported here. Therefore, it is not possible to
calculate a true estimate of the cumulative incidence of this
phenomenon. As the number of cases is likely higher than
those discovered, the incidence of isolated CMCA is likely no
lower than the estimated incidence of discovered cases of
2.3% (95% CI, .8% to 3.8%). Other groups have also reported
rare instances of isolated clonal cytogenetic abnormalities
after ASCT [2,9,13-19], but to our knowledge this is 1 of the
largest single series of such patients. The only larger series
was limited to patients with MM [9]. Moreover, the previous
reports often included cytogenetic abnormalities that were
not clonal or were normal variants. Table 4 summarizes the
ﬁndings regarding only the isolated clonal cytogenetic ab-
normalities from these studies [2,9,14-19]. The largest series
published reported 79 of 2418 patients who developed
Table 2
Characteristics of Patients Who Developed t-MN after High-Dose Therapy
Patient No. Dx Previous Treatments Status
at HDT
HDT Prep Years from
HDT to t-MN
Outcome (years
from HDT)
Time after
HDT, yr
Cytogenetic Results
1. AA Prednisone Active HiCy 12.9 Alive with MDS (15.2) Pre 46,XX[19]
.5 46,XX[20]
1 46,XX[10]
2 46,XX[20]
12.9 45,XX,-7[4]/45,idem,del(20)
(q12)[4]/46,XX[2]
13 45,XX,-7[9]/46,XX[11]
2. AML HDACþ
duano, HDACþ
VP16
CR1 BuCy 2.2 Dead* (6.5) Pre 46,XY[20]
.3, .6 46,XY[20]
1, 1.4 46,XY[20]
2.2 46,XY,þ1,der(1;7)(q10;p10)[8]/46,XY[12]
3 46,XY,þ1,der(1;7)(q10;p10)[5]/46,XY[15]
4 46,XY,þ1,der(1;7)(q10;p10)[9]/47,idem,þ8[11]
5.8 47,XY,þ8[1]/47,XY,þ1,der(1;7)
(q10;p10),þ8[16]/46,XY[3]
3. CLL FluCy  4 PR1 CyTBI 5.2 Dead (5.7) NA
4. CLL Flu  6
CHOP  2
FluCy  2
CR1 BuCy 3.1 Dead (6.6) .1 46,XY[21]
3.1 49-52,XY,þ6,þ8,þ10,þ11,i(17)
(q10),þ22[cp19]/46,XY[1]
5. DLBCL CHOP  6
ESHAP  2
REL1 CyTBI 3.2 Dead (5.6) 3.2 -7 per note
3.5 -7 per note
3.9 45,XX,-7[19]/46,XX[1]
4.3 46,XX,-7,þ21[2]/46,XX[7]
4.6 46,XX,-7,þ21[1]
4.8 46,XX,-7,þ21[11]/46,XX[9]
5.1 46,XX,-7,þ21[9]/46,XX[1]
6. DLBCL CHOP  6 CR1 BuCy 2.8 Dead (2.9) 2.8 45,XY,-7[1]/44,XY,add(4)(q21),-7,add(18)
(p11.3),-20, add(21)(q22)[19]
2.9 44,XY,add(4)(q21),-7,add(18)(p11.3),-20, add(21)
(q22)[15]/44,idem,add(19)(p13.3)[5]
7. DLBCL RCHOP  6 RICE  2 CR2 CyTBI 1.3 Dead (1.7) 1.3 -5q (66%) -20q(77%) FISH
8. DLBCL CVP  8,
RCHOP REPOCH
REL1 BuCy 2.7 Dead (3.6) 2.7 46,XX,-7[13]/45,idem,-6,add(10)(q11.2),add(12)
(p12), add(20)(p13),þmar[7]
2.8 44-45,XX,-6,-7,-12, add(20)(p13),þmar1,þmar2[cp5]/46,XX[5]
9. DLBCL RCHOP  2 RESHAP PR2 BuCy 2.1 Dead (2.9) 2.1 46,XY,del(7)(q22)[18]/46,XY[2]
2.2 46,XY,del(7)(q22)[20]
2.4 46,XY,del(7)(q22)[17]/46,XY[3]
10. DLBCL RCHOP  6
ESHAP  1
RT
PR2 CyTBI 8.8 CR (9.2) 8.8 47,XY,þ8[2]/46,XY[18]
8.9 47,XY,þ8[3]/46,XY[17]
9.2 46,XY[20]
11. DLBCL CHOP  6
ICE  3
CR2 BuCy 4.3 Dead (4.8) Pre 46,XY[20]
4.3 43,XY,der(5;17)(p10;q10),-7,der(19)t(19;20)
(p13.1;p11.2),-20[3]/44,idem,þmar[6]/46,XY[11]
12. MM MP  4
VAD  2
PR2 BuCy 2.5 Dead (3.0) 1.3 Complex including add(5),dup(6),del(11),del(15) per note
2.5 45,XX,-5,dup(6),dup(12)-18,-21 per note
2.8 45,XX,-5,trp(6)(p12p21),ins(12;?)(q13;?),-18,þmar[14]/45,idem,
11,der(18)t(1;18)(q12,q21)[3]/45,idem,del(20)(q12)[3]3/44,idem,
t(X;21)(q2w4;q22)[2]
13. iNHL FluCy  4 PR1 CyTBI 9.3 Dead (9.7) 9.3 48,XY,?inv(4)(p15.2q33),del(7)(q34),þ8,þ11[20]
14. iNHL FluCy  4 CR1 CyTBI 4.0 Dead (4.7) 4 47,XY,þ8[20]
(continued on next page)
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Table 2
(continued )
Patient No. Dx Previous Treatments Status
at HDT
HDT Prep Years from
HDT to t-MN
Outcome (years
from HDT)
Time after
HDT, yr
Cytogenetic Results
15. iNHL ProMACE-CytaBOM,
RT
REPOCH  2
REL1 BuCy 3.0 Dead (4.8) 3 46,XY,inv(14)(q11.2q32)[2]/46,idem,t(6;6)(p11.2;q25)
[3]/46,XY,del(13)(q12q14)[2]/46,X,del(Y)(q11.2q12),
add(12)(p12)[2]/46,XY[27]
3.6 46,XY,add(6)(q25),-7,add(11)(p15),del(17)(q21)[2]/46,XY[15]
4 46,XY[30]
16. iNHL RCHOP  6 CR1 CyTBI 2.0 Dead (2.5) .2, .5 46,XY[25]
2 45,XY,add(1)(p36.1),add(5)(q15),-7,add(9)(p11),-19,
þmar[17]/46,XY[3]
17. iNHL CVP  8
RCHOP  3
REL2 HiCy 4.1 Dead (4.2) 1.0, 1.3 46,XX[26],[20]
1.5, 1.7 46,XX[20]
18. iNHL CHOP þ
HDMTX  8
RT
RESHAP  2
REL1 CyTBI .8 Dead (.8) .2 46,XY[25]
.8 46-48,XY,t(1;21)(q12;q11.2),-7,der(7;10)(p10;q10),-10,
add(11)(p14),der (12)t(1;12)(q21;q13), add(13)(p11.2),
-17, add(19)(p13.3),þi(19)(q10),þ14mar[cp9]
19. iNHL CHOP  7 PR1 CyTBI 5.4 Dead (7.3) 3.6, 3.8 46,XY[20],[21]
5.4 del(5),-7,-8,der(12),add(17)[11]/t(13;15)[2]/46,XY[7]per note
20. iNHL Flu  5 PR1 CyTBI 6.3 Dead (7.9) .1 46,XY[20]
3.1 46,Y,t(X;1)(q26;q21),t(7;13)(p12;q32),del(10)(q22)
[6]/46,Y,t(X;12)(q26;q13), der(7)del(7)(p11.2p14)add(7)
(q22),inv(7)(q11.2q22)[2]/46,XY[16]
6.3 t(X;1),t(7;13),del(10)[2/20] per note
6.4 þ2,del(5), del(7),inv(11),t(8;12) [2/20] per note
7.3 46,Y,t(X;12)(q26;q13),der(7)del(7)(p11.2p14)add(7)(q22),inv(7)(q11.2q22)
[6]/46,XY,del(7)(q22q32), inv(11)(p11.2q25),add(12)(q24)[2]/46,Y,
t(X;1)(q26;q21),t(7;13)(p12;q32),del(10)(q22)[1]/46,XY[8]
21.y iNHL CHOP  6 CR1 CyTBI 2.3 Dead (2.6) Pre 46,XY[25]
.2 46,XY[25]
.8 46,XY,t(1;2)(p13;q31),t(5;18)(q33;q22),t(8;17)(q22;p13),inv(10)
(p11.2q26)[8]/46,XY[12]
1.0 46,XY,t(1;2)(p13;q31),t(5:18)(q33;q22),t(8;17)(q22;p13), inv(10)
(p11.2q26)[16]/46,XY[9]
2.0 46,XY,t(1;2)(p13;q31),t(5;18)(q33;q22),t(8;17)(q22;p13),inv(10)
(p11.2q26)[20]
22. iNHL RCHOP  3
RICE  2
PR1 BuCy 4.4 Dead (5.5) .2, .5 46,XX[20]
1, 2 46,XX[20]
4.4 complex per note
4.8 45,XX,der(5;17)(p10;q10),-13,add(22)(q13),þmar[10]
5.0 45,XX,der(5;17)(p10;q10),-13,add(22)(q13),þmar[6]/46,sl,þ8[3]
Dx indicates diagnosis; HDT, high-dose therapy; Pre, before HDT; NA, not available; CR, complete remission; UNK, unknown; REL, relapse; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; ABVD,
doxorubicin, bleomycin, vinblastine, dacarbazine; RESHAP, Rituxan, etoposide, methylprednisolone, cytarabine, cisplatin; RT, radiation therapy; HCVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; E2993,
chemotherapy modeled after ECOG 2993 trial; TBI, total body irradiation; Bu, busulfan; Cy, cyclophosphamide; HD, high dose; M, melphalan; P, prednisone; T, thalidomide; dauno, daunorubicin; EPOCH, etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin; CVP, cyclophosphamide, vincristine, prednisone; VAD, vincristine, doxorubicin, dexamethasone; Flu, ﬂudarabine; ProMACE, prednisone, etoposide, doxorubicin, cyclophosphamide;
CytaBOM, cytarabine, bleomycin, vincristine, methotrexate, leucovorin; AC, cytarabine; PR, partial remission; RICE, rituximab, ifosfamide, carboplatin, etoposide; t-MN, therapy-related myeloid neoplasms; AA, aplastic anemia;
iNHL, indolent non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; CLL, chronic lymphocytic lymphoma; MM, multiple myeloma; AML, acute myeloid leukemia, MDS, myelodysplastic syndrome.
* Causes of death: Patient nos. 2, 5, 6, 15, 16, and 20 died of infection in the setting of refractory t-MN. Patient no. 3,4,7,8, 12-14, and 21 were discharged to home institutions or hospice for supportive care in the setting of active
t-MN, and subsequently succumbed to their disease. Patient nos. 9 and 19 died of infection in the setting of refractory GVHD after allogeneic SCT for t-MN. Patients 11, 17, and 18 died of complications of relapsed NHL in the
setting of active t-MN.
y Patient 21 had normal bone marrow pathology on all 4 biopsies listed. Then, at 2.3 years from HDT, a bone marrow biopsy performed at an outside hospital was consistent with t-MN, but those results were unavailable.
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Table 3
Characteristics of Patients Who Developed Isolated CMCA after High-Dose Therapy
Pt No. Dx Previous
Treatments
Status at HDT HDT Prep Outcome (years
from HDT)
Time after
HDT, yr
Cytogenetic Results WBC (13
per mm3)
HCT (%) PLT (103
per mm3)
1. AA None Active HiCy CR (5) Pre 46,XX[20] 3.8 11.3 8
3.4 -7[7/20] per note 3.8 34.6 62
3.6 46,XX[20] 3.3 33.5 29
3.8 46,XX[20] and FISH AML proﬁle WNL NA NA NA
2. AA None Active HiCy CR (3.3) Pre NA .43 15.8 2
1 47,XX,þ22[8]/46,XX[12] 1.7 27.3 10
3.3 46,XX [26] 2.2 24.3 11
3. DLBCL RCHOP  5
RICE  5
CR2 CyTBI CR (8.5) Pre NA 4.8 26.2 167
1 46,XX [25] 4.6 37.2 93
2 46,XX,del(7)(q31q35)[4]/46,XX[16] 5.8 33.8 134
3 46,XX[20] 5.8 38.6 151
4. HL ABVD  8
ESHAP  3
REL1 BuCy CR (7.3) pre NA 3.8 28.1 134
.2 46,XY[20] 2.3 26.8 34
.9 46,XY,t(1;9)(p22;p13)[2]/46,XY[29] FISH AML and MM proﬁle WNL 1.7 25.6 21
1, 2 46,XY[20] 5.5 38.1 51
3 46,XY,t(1;9)(p22;p13)[1]/46,XY[19] 6.5 36.0 100
5. AA None Active HiCy CR (7.2) Pre 46,XX[1] 1.8 25.4 8
3 46,XX,inv(7)(q11.2q22)[20] 3.0 33.7 55
6. ALL E2993 CR1 CyTBI CR (9.9) Pre 46,XY[20] and FISH BCR/ABL WNL 1.9 29.2 84
.3 46,XY,add(1)(p32),t(2;8)(q12;p23),t(3;17)(p21;q22),t(7;8)(q32;q13),
-12, del(13)(q12q14),þmar[3]/46,XY[8] and FISH wnl :BCR/ABL
2.4 32.1 23
1.3 46,XY,t(8;21)(q22;p11.2)[4]/46,XY,add(1)(p32),t(2;8)(q12;p23),
t(3;17)(p21;q22), t(7;8)(q32;q13),-12,del(13)(q12q14),
þmar[6]/46,XY[9]
1.9 31.0 9
2.5 46,XY,t(8;21)(q22;p11.2)[5]/46,XY,add(1)(p32),t(3;17)(p21;q22),
del(5)(p11.2), t(6;12)(q21;q15),t(7;8)(q32;q13),-12,del(13)(q12q14),
þmar[cp11]/46,XY[4] and FISH BCR/ABL negative
3.2 41.3 18
9.1 46,XY,del(13)(q12q14)[4]/46,sl,t(2;8)(q12;p23),t(3;17)(p21;q22),
t(7;8)(q32;q13),-12,þmar[2]/46,XY[8] and FISH BCR/ABL WNL
5.7 41.4 114
9.9 46,XY,del(13)(q12q14)[5]/46,XY,t(8;21)(q22;p11.2)[1]/46,XY,
-1,add(3)(p21),add(12)(q24.3),-15,-20,þ3mar[3]/46,XY,add(1)
(p32), t(2;8)(q12;p23),t(3;17)(p21;q22),t(7;8)(q32;q13),
-12,del(13)(q12q14), þmar[4]/46,XY[6] and FISH BCR/ABL WNL
5.7 37.3 124
7. CLL Flu  3
Chlr  6
PR1 CyTBI CR (11.3) Pre NA 4.7 30.8 90
6.3 46,X,t(Y;15)(p11.2;q11.2),t(11;12)(p15;q13),del(20)(q12)[9]/46,XY,
t(2;7)(q33;p13),t(2,10;6)(q31;q22;q25),t(9;21;15)(q22;q22;q15),
-20,del(20)(q11.2),þ22[6]/46,XY[8]
3.2 38.9 112
8.8 46,XY,t(2;7)(q33;p13),t(2;10;6)(q31;q22;q25),t(9;21;15)
(q22;q22;q15),-20,del(20)(q11.2),þ22[19]/46,X,t(Y;15)
(p11.2;q11.2),t(11;12)(p15;q13),del(20)(q12)[2]/46,XY[1]
4.2 44.3 145
10.2 46,X,t(Y;15)(p11.2;q11.2),t(11;12)(p15;q13),del(20)(q12)
[14]/46,XY[6] and FISH AML proﬁle del(20q) 48%
3.5 41.1 131
11.2 del(20q) 37% FISH 4.3 41.8 146
8. DLBCL RT
CHOP  6
CR2 BuCy Dead (3) Pre NA 6.9 23.0 588
.2 46,XX[20] 7.0 32.5 277
.5 46,XX[20] and FISH BCR/ABL WNL 4.7 42.5 229
1 46,XX[20] 5.8 37.4 271
2 46,XX,del(7)(q22)[2]/46,XX[18] 6.0 36.1 412
(continued on next page)
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Table 3
(continued )
Pt No. Dx Previous
Treatments
Status at HDT HDT Prep Outcome (years
from HDT)
Time after
HDT, yr
Cytogenetic Results WBC (13
per mm3)
HCT (%) PLT (103
per mm3)
9. DLBCL CHOP  4
RT
REL1 BuCy CR (11.6) Pre NA 9.1 26.7 159
3.0 46,XY[21] 4.4 33.9 62
9.6 del(20)(q11.2q13.3) [5/20] per note
and FISH positive: del(20q) per note
4.2 21.0 97
10 FISH AML proﬁle WNL 4.0 35.8 97
10.* iNHL HCVAD  5 CR1 CyTBI CR (7.5) Pre NA 3.9 29.9 218
.3 46,XY[25] 6.3 35.8 185
.5 46,XY[25] 7.0 35.6 179
1 45,X,-Y[7]/46,XY[18] 5.2 42.3 212
2 45,X,-Y[6]/46,idem,þ15[2]/46,XY[12] 6.5 40.7 276
3 45,X,-Y[4]/46,X,-Y,þ15[3]/46,XY[13] 6.9 39.5 268
5 45,X,-Y[3]/46,idem,þ15[4]/46,XY[18] 7.3 40.1 279
11. iNHL RCHOP  6 CR1 HiCy CR (5.3) Pre NA 7.5 37.9 231
3.3 45,X,-Y[11]/46,XY,del(20)(q13.1)[10] 1.9 35.5 120
5.3 46,XY,del(20)(q13.1)[14]/45,X,-Y[6] 5.0 33.8 139
Dx indicates diagnosis; HDT, high-dose therapy; HCT, hematocrit; PLT, platelet; Pre, before HDT; AML, acute myeloid leukemia;WNL, within normal limits; NA, not available; CR, complete remission; UNK, unknown; REL, relapse;
RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, andprednisone;ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ESHAP, etoposide,methylprednisolone, cytarabine, cisplatin; RT, radiation therapy;HCVAD,
cyclophosphamide, vincristine, doxorubicin, dexamethasone; E2993, chemotherapymodeled after ECOG 2993 trial; TBI, total body irradiation; Bu, busulfan; Cy, cyclophosphamide; HD, high dose; M, melphalan; P, prednisone; T,
thalidomide; dauno, daunorubicin; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; CVP, cyclophosphamide, vincristine, prednisone; VAD, vincristine, doxorubicin, dexamethasone; Flu, ﬂudarabine;
ProMACE, prednisone, etoposide, doxorubicin, cyclophosphamide; CytaBOM, cytarabine, bleomycin, vincristine, methotrexate, leucovorin; AC, cytarabine; RICE, rituximab, ifosfamide, carboplatin, etoposide; Chlr, chlorambucil;
CMCA, clonal marrow cytogenetic abnormalities; AA, aplastic anemia; HL, Hodgkin lymphoma; iNHL, indolent non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; CLL, chronic lymphocytic lymphoma; PR1, ﬁrst partial
response; ALL, acute lymphoblastic lymphoma; MM, multiple myeloma; AML, acute myeloid leukemia.
Results denoted “per note” were only available from clinician notes, and the corresponding analyses were not done at our institution.
FISH results: In cases where more than 1 probe was tested, the name of the proﬁle is stated and contain the following probes: AML FISH proﬁle: 5p15.2, 5q31, 7cen, 7q31, 8cen, 11q23, 20pter, 20q12.
Multiple myeloma (MM) FISH proﬁle: 3cen, 7cen, 9cen, 15cen, 11q13, 14q32, 13q14, 13q34, 14q32, 17cen, 17p13.1 The MM proﬁles were not done at our institution.
* Patient 10: Loss of chromosome Y was considered a normal variant not a cytogenetic abnormality.
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Table 4
Summary of Published Reports of Isolated CMCA after High-Dose Therapy
Author No. Pts Evaluable
of Total
Diagnoses Pts with CMCA and
Diagnosis
Follow-up Time from
ASCT, mo
Months from
ASCT to CMCA
Transient Persistent Cohort, Median Positive Pts
Imrie 62 of 76 AML 2 4 39 4, median 20, median
Laurenti 66 of 225 NHL, MM, CML, HL 2 HL 0 25 67 and 49 32 and 16
Perot 66 of 114 AML, ALL 4 7 NA 46, median 20, median
Deliliers 83 of 109 NHL, HL, AML, ALL, MM 3 AML 0 47 NA 3-12
Soligo 31 NHL, HL 0 2 NA 18 and 18 12 and 18
Martinez-Climent 60 of 229 Breast 2 1 36 NA 12,12, and 18
Basecke* 53 of 56 DLCL, CLL 1 DLCL 1 CLL 48 45 and 12 12 and 12
Barlogie 2418 of 3077 MM 54 25 NA NA 5-124
AML indicates acute myeloid leukemia; NHL, non-Hodgkin leukemia; MM, multiple myeloma; CMCA, clonal marrow cytogenetic abnormalities; CML, chronic
myeloid leukemia; HL, Hodgkin’s lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; DLCL, diffuse large B cell lymphoma; ASCT,
autologous blood or marrow transplantation, Pts, patients; HDT, high-dose therapy.
This table includes only patients who meet the same criteria for isolated CMCA used in our study. Patients without cytogenetic analysis at diagnosis who died of
relapsed AML after HDT were not considered isolated CMCAs, as per our methodology.
* Though 3 patients were reported with aberrant clones, only 2 had completed HDT.
M.M. Showel et al. / Biol Blood Marrow Transplant 20 (2014) 1130e1138 1137CMCAswithout t-MN, two thirds of which were transient [9].
Imrie et al. reported ﬁndings comparable to ours: 6 of 62
patients treated with ASCT for AML developed isolated
CMCA, including 2 which were transient [14]. Perot et al.
reported 7 of 66 patients with persistent and 4with transient
isolated CMCA [17].
It is impossible to know if the isolated CMCA originated
from hematopoietic progenitors that were damaged during
conventional treatment before HDT or rather were damaged
during high-dose conditioning. Regardless of when the
damage occurred, the observed aberrant clones apparently
lacked the ability to transform into malignant clones during
the period of follow-up. Transient clonal hematopoiesis
could be the result of mutations occurring in hematopoietic
progenitors with limited self-renewal capacity. Moreover,
normal hematopoietic progenitors acquire DNA mutations
with age that are probably benign and not associated with
malignant progression [32]. Therefore, perhaps it is not
surprising that in patients who have been exposed to agents
known to cause DNA damage and have frequent bone
marrow analysis, gross genetic mutations (CMCA) that are
not related to malignancy would be discovered.
The SAA group further highlights the importance of CMCA
that may not represent t-MN. Of those 4 patients who
developed cytogenetic abnormalities, only 1 has developed
t-MN as of the last follow-up. Because of their reported
increased risk of developing MDS/AML [14,33], their
increased incidence of clonal cytogenetic abnormalities [34],
and the fact that these patients have cytopenias after HDT,
patients with AA may be more likely to be diagnosed with
MDS in the setting of isolated CMCA. Therefore, it would be
particularly important in this population to note that all
CMCA may not be associated with t-MN.
Though there were some differences between patients
with t-MN and those with detected isolated CMCA, these
differences did not deﬁnitively distinguish the 2 groups.
Compared with those that developed t-MN, the cohort in
whom CMCAwere discovered received less cytotoxic therapy
before and during HDT. The abnormal clone involved a me-
dian of only 39% of cells in patients with isolated CMCA
compared with 83% of cells when the abnormality occurred
with t-MN. Isolated CMCA were detected sooner after HDT
than CMCA associated with t-MN, 2.0 (range, .3 to 9.6) versus
3.1 (range, .8 to 12.9) years respectively; however, there is
signiﬁcant overlap in these time intervals. In addition, 3
patients who developed t-MN initially had CMCA thatpresented with normal bone marrow pathology, preceding
the deﬁnitive morphologic diagnosis of MDS/AML. The cy-
togenetic abnormalities in both groups were similar. Alto-
gether, CMCA were found in 31 patients, only 20 of whom
developed t-MN during the follow-up period. The proportion
of CMCA associated with t-MN cannot be calculated deﬁni-
tively for several reasons: as all patients did not have kar-
yotype evaluation at all time points, all cases of isolated
CMCA would not be discovered; undoubtedly some bone
marrow biopsies were done because of peripheral blood
count abnormalities or other clinical abnormalities, resulting
in a higher likelihood that t-MN would be discovered; and
those patients with identiﬁed isolated CMCA could still
develop t-MN with longer follow-up. Despite these limita-
tions, our data suggest that not all patients with isolated
CMCA develop t-MN. Taken together, these ﬁndings have
signiﬁcant clinical implications, as the only curative treat-
ment option for t-MN is allogeneic SCT with its high risk of
morbidity andmortality. Moreover, early allogeneic SCT for t-
MNwould seem to bemost effective. However, after HDT, the
development of CMCA alone, even if persistent, should not be
used as the sole criteria to diagnose t-MN. Morphologic
changes in the bone marrow diagnostic of t-MN should also
be present.
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